Tag: M&A

Amgen Acquired 20.5% Stake in BeiGene for $2.8bn

S-based Amgen has closed the acquisition of a 20.5% stake in Chinese biopharmaceutical firm BeiGene for approximately $2.8bn to support the expansion of its oncology footprint in China. BeiGene...

Charles River Laboratories Completed Acquisition of HemaCare Corporation for $380m

Charles River Laboratories International, Inc. announced that it has completed the previously announced acquisition of HemaCare Corporation for approximately $380 million in cash, or $25.40 per HemaCa...

Top M&A Pharma Deals in 2019

The year was marked by mergers and acquisitions (M&A) both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019. Bristol-Myers Squibb Buys Celgene The y...

GSK Completed Sale of Rabipur and Encepur to Bavarian Nordic

gsk
GlaxoSmithKline (GSK) has completed the sale of its travel vaccines Rabipur for rabies, and Encepur for tick-borne encephalitis, to Bavarian Nordic. Under the terms of the transaction agreement...

Pharming to Reacquire Commercial Rights to RUCONEST® from Sobi

Pharming Group N.V. announced it has entered into a definitive agreement with Swedish Orphan Biovitrum AB (publ) (“Sobi”) to reacquire the commercial rights to Pharming’s product, RUCONEST®, in ...

Organovo Holdings and Tarveda Therapeutics Completed Merger

Organovo Holdings and Tarveda Therapeutics, a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to a...

XBiotech Closed Sale of True Human Antibody Bermekimab to Janssen

monoclonal antibodies
XBiotech Inc. announced the closing of the sale of the Company's True Human antibody Bermekimab to Janssen Biotech, Inc. (Janssen), a Janssen Pharmaceutical Company of Johnson & Johnson. Upon c...

LEO Pharma Sold 10 Products to Karo Pharma AB

leo-pharma
LEO Pharma announced the sale of 10 products to Karo Pharma AB for 90 MEUR. The divested portfolio is non-core to LEO Pharma’s business and was part of the portfolio acquired from Bayer in July 2019. ...

Astellas Acquired Xyphos

astellas
Astellas Pharma Inc. and Xyphos Biosciences, Inc. announced that Astellas has acquired Xyphos. With the acquisition Astellas will gain Xyphos' novel and proprietary ACCEL (Advanced Cellular Control th...

Towa Acquired Esteve Generics Division

TOWA PHARMACEUTICAL CO., LTD. and ESTEVE announced that TOWA will acquire 100% ownership of Pensa Investments, S.L., the generics division of the Spanish pharmaceutical company ESTEVE. The purchase pr...

Johnson&Johnson Announced Agreement to Acquire Remaining Stake in Verb Surgical

JohnsonJohnson
Dedicated to shaping the next frontier of surgery, Johnson & Johnson announced an agreement to acquire the remaining stake in Verb Surgical Inc. following a successful strategic collaboration with...

Astellas Set to Acquire Audentes

Astellas Pharma Inc. announced that it has commenced, through its indirect, wholly-owned subsidiary Asilomar Acquisition Corp., a tender offer for all of the issued and outstanding shares of common st...

Merck Animal Health Announced Completion of Acquisition of Vaki

Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, announced the completion of its acquisition of Vaki, a leader in fish farming and wild fish conservation monitoring equ...

Charles River Laboratories Agreed to Acquire HemaCare for $380m

Charles River Laboratories International has agreed to acquire human-derived cellular products provider HemaCare for around $380m in cash. HemaCare has expertise in the customisation of human-d...

3M Agreed to Sell Drug Delivery Business to Altaris Capital Partners for $650m

3M, a US-based manufacturing company, has agreed to sell almost all of its drug delivery business to an affiliate of Altaris Capital Partners for about $650m. According to 3M, the total conside...

UK Cleared Roche’s Proposed Purchase of Spark Therapeutics

The UK Competition and Markets Authority announced the clearance of Roche's proposed purchase of Spark Therapeutics after concluding that the deal would not negatively affect competition for haemophil...